KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied ...

ADHERE enrolled 322 adult patients with CIDP who were treatment naïve (not on active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin ... In binding to the ...

TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains ... Domvanalimab is Fc-silenced, meaning it does not bind to the Fc receptors found on immune cells, thereby leaving those ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an important ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the anti-A proliferation-inducing ligand (APRIL) monoclonal antibody, CLYM116 ...

With an Fc-engineered design, CLYM116 targets APRIL signalling, a key factor in B-cell-mediated diseases. The antibody's mechanism of action includes blocking APRIL's binding to its receptors and ...

evaluate Fc-dependent functional antibodies ... underlie the differences observed in Fcγ-receptor-binding (types I, IIa, and IIIa/b), IgG, IgM, and IgA production, and complement-fixing antibodies.

CeRMS (Center for Research and Medical Studies), A.O. Città della Salute e della Scienza di Torino, Torino, Italy. Department of Orthopaedics, A.O. Città della Salute e della Scienza di Torino, Torino ...